Moderna, Merck shares rise as combined melanoma therapy shows improved survival rate
) and Merck have released new, more encouraging three-year data on their experimental vaccine for the most deadly form of skin cancer.
The vaccine, a critical component of Moderna’s pipeline, has bolstered investor confidence following a challenging period last year when demand for its Covid vaccine, currently its only commercially available product, significantly declined. The new data builds on initial results announced by the companies in December.In the latest findings, nearly 75% of patients receiving the combination treatment were alive without any signs of cancer recurrence at the 2½-year mark, compared to 55.
As previously announced by the companies, patients with severe melanoma who received the combination therapy were 49% less likely to die or experience a recurrence than those who took Keytruda alone over approximately three years. Moreover, the combination therapy reduced the risk of melanoma spreading to other parts of the body or causing death by 62%.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna, Merck say vaccine improved survival in patients with deadly skin cancerNearly 75% of patients who took the cancer vaccine and Keytruda were alive without any signs or symptoms of their cancer returning at the 2½-year mark.
Read more »
Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conferenceCNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.
Read more »
Merck to acquire eye drug company EyeBio for up to $3 billionMerck to acquire eye drug company EyeBio for up to $3 billion
Read more »
Moderna and this solar name are among the most overbought stocks after a record-setting weekCertain stocks this week became overbought, based on their 14-day relative strength index, or RSI.
Read more »
Salesforce, Kohl's and Agilent fall premarket; Foot Locker, Moderna riseSalesforce, Kohl's and Agilent fall premarket; Foot Locker, Moderna rise
Read more »
Moderna and Pfizer competing for HHS bid on mRNA vaccines for bird fluModerna and Pfizer are both competing for federal contracts with HHS to contribute to an mRNA vaccine stockpile in case the H5N1 virus spreads to humans.
Read more »